The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Teva's 2013 sales performance.
The drug was third to market in the class, coming behind first place winner Aimovig (erenumab) from Amgen and second entrant Ajovy (fremanezumab) from Teva.
A successful outcome in those studies would make the drug a potential competitor to three CGRP inhibitors given by subcutaneous injection – Amgen/Novartis’ Aimovig (erenumab), Teva’s Ajovy (fremanezumab) and
Teva has however claimed an FDA approval for a three-month regimen for Ajovy. ... Teva meanwhile said Ajovy made $96m last year, while Lilly reported Emgality sales of $163m.
Drug wasn't able to improve on placebo. Teva’s effort to reinvigorate its business with new product launches has suffered a setback after a drug for Tourette’s syndrome failed ... Deutetrabenazine was acquired by Teva when it bought Auspex Pharma
A number of major generic drugmakers have also been accused of antitrust practices, including Teva Pharmaceuticals, Sandoz, Mylan and Pfizer – all were named in a wide-ranging lawsuit filed in May
[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]
Evoke Kyne is an award-winning communications agency that harnesses insight, experience and creativity to advance health and wellbeing around the world. We were founded on the belief that...